CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Study Summary

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

Interventions

Study Locations

Facility	City	State	Country
920th Hospital of Joint Logistics Support Force	Kunming	Yunnan	China

Official Trial Information

View on ClinicalTrials.gov